High Quality Powder Blonanserin CAS 132810-10-7

Blonanserin, as an atypical antipsychotic, is primarily indicated for the treatment of schizophrenia. It features tailored medication strategies for different disease stages and special populations, while also demonstrating significant efficacy in improving patients' cognitive and social functions. 

Blonanserin (also known as AD-5423 or Lonasen®) is a novel atypical antipsychotic agent developed by Dainippon Sumitomo Pharma, first approved in Japan in 2008 and subsequently in South Korea, India, and China for the treatment of schizophrenia . It functions as a potent antagonist at dopamine D₂/D₃ receptors and serotonin 5-HT₂A receptors, which are key targets for antipsychotic efficacy . Unlike first-generation antipsychotics such as haloperidol, blonanserin has demonstrated superior efficacy in treating negative symptoms while maintaining a favorable extrapyramidal side effect profile . A unique transdermal patch formulation, the first of its kind for an antipsychotic, was approved in Japan in September 2019, offering an alternative route of administration for patients who have difficulty with oral medication or those in palliative care settings . Meta-analyses have confirmed that blonanserin has comparable efficacy to other atypical antipsychotics such as risperidone and olanzapine, with a distinct tolerability profile characterized by lower risks of prolactin elevation and weight gain .